Investing in biotech stocks might seem compelling, but it might be a high-risk, high-reward strategy, especially if these companies are in the pre-revenue stage. However, according to scientists, we are in the golden age of biotechnology, making the sector extremely attractive to investors.
A number of biotech companies have drugs targeting multiple diseases in the pipeline, which, if they are approved by regulators, should allow them to deliver outsized gains. One such biotech stock is Ultragenyx Pharmaceutical (RARE), which is valued at $3.44 billion by market cap.
